BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 131, Issue 1, Pages -
Publisher
American Society for Clinical Investigation
Online
2021-01-04
DOI
10.1172/jci133090
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MYC protein stability is negatively regulated by BRD4
- (2020) Ballachanda N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface
- (2020) Mingxing Teng et al. ACS Medicinal Chemistry Letters
- BCL6 evolved to enable stress tolerance in vertebrates and is broadly required by cancer cells to adapt to stress
- (2019) Tharu M Fernando et al. Cancer Discovery
- Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma
- (2019) Kewen Hu et al. JOURNAL OF CLINICAL INVESTIGATION
- SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis
- (2018) Matthias Muhar et al. SCIENCE
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
- (2018) Xin Jin et al. MOLECULAR CELL
- Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery
- (2018) Hui-Ju Hsieh et al. Nature Communications
- Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease
- (2018) Katelyn Paz et al. BLOOD
- Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach
- (2017) Yusuke Kamada et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
- (2017) Takao Fujisawa et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- BCL6 promotes glioma and serves as a therapeutic target
- (2017) Liang Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
- (2017) Nina Kerres et al. Cell Reports
- EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
- (2016) Wendy Béguelin et al. CANCER CELL
- The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target
- (2016) Mariano G. Cardenas et al. CLINICAL CANCER RESEARCH
- Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
- (2016) Mariano G. Cardenas et al. JOURNAL OF CLINICAL INVESTIGATION
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Genome-wide Analysis Identifies Bcl6-Controlled Regulatory Networks during T Follicular Helper Cell Differentiation
- (2016) Xindong Liu et al. Cell Reports
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Refining the treatment of NSCLC according to histological and molecular subtypes
- (2015) Anish Thomas et al. Nature Reviews Clinical Oncology
- Dragging Ras Back in the Ring
- (2014) Andrew G. Stephen et al. CANCER CELL
- DAPK2 is a novel regulator of mTORC1 activity and autophagy
- (2014) Y Ber et al. CELL DEATH AND DIFFERENTIATION
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- The transcriptional modulator BCL6 as a molecular target for breast cancer therapy
- (2014) S R Walker et al. ONCOGENE
- Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis
- (2014) Zhe Chang et al. PLoS One
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- The Bcl6-SMRT/NCoR Cistrome Represses Inflammation to Attenuate Atherosclerosis
- (2012) Grant D. Barish et al. Cell Metabolism
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
- (2011) Cihangir Duy et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas
- (2011) Shanshan Duan et al. NATURE
- Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes
- (2011) J. M. Lamonica et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast Cancer
- (2009) Yan Wang et al. CELL
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
- (2009) Michel DuPage et al. Nature Protocols
- A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
- (2008) L. C. Cerchietti et al. BLOOD
- DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function
- (2008) A Britschgi et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now